Latest News and Press Releases

Christoph Baldegger, primary insider and member of the board of directors in Hofseth BioCare ASA ("HBC") has today purchased 100,000 shares in HBC at an average price of NOK 2.72 per share. As a...

Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 ...

Hofseth International AS ("HI"), a close associate of Hofseth Biocare ASA's (the "Company") board member Roger Hofseth, has notified the Company that HI has made the following purchases of shares in...

In Q4, the ingredients business continued to show favorable momentum with growth of 87 %, compared to same quarter last year on an underlying basis, generating sales revenues of NOK 34m, compared to...

Ødegård Prosjekt AS, a wholly owned company of Jon Olav Ødegård has today, 30 December 2022, bought 70,000 shares at an average price of NOK 2.91 per share. Jon Olav Ødegård is CEO and primary insider...

Highlights in the third quarter - HBC grew revenue by 105 % year-on-year shows strength of our business in uncertain times and during the third quarter, HBC signed contracts with new salmon...

The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and Stanford University School of Medicine. It aimed...

The Extraordinary General Meeting in Hofseth BioCare ASA was held at the premises of the Company in Ålesund, Norway today Tuesday 30 August 2022. All matters were approved according to the...

Hofseth BioCare ASA is yet again part of an Exclusive Short-List of Companies to Have Successfully Notified FDA while receiving a No Objection Letter for ProGo® Bioactive Peptides. Summary Highlights...

HBC had gross operating revenues of NOK 25.8m (31.0m) in the second quarter. For the first half of 2022 HBC had revenues of NOK 56.6m (47.9m). Cost of sales (CoGS) amounted to NOK 17.7m (21.6m) in the...